Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.
Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.
复制标题
DOI：
10.1155/2013/450639
复制
发表时间：
2013
影响因子：
2.8
通讯作者：
Migdalis IN
中科院分区：
文献类型：
--
作者：
Mavrogiannaki AN;Migdalis IN
非酒精性脂肪性肝病（NAFLD）是全球最常见的慢性肝病。在这一疾病谱中，单纯的脂肪变性显然是良性的，而非酒精性脂肪性肝炎可能进展为肝硬化和肝细胞癌。NAFLD与肥胖、血脂异常、2型糖尿病和心血管疾病密切相关。肝脂肪变性的发病机制尚不清楚，但其主要特征被认为是胰岛素抵抗、线粒体功能障碍、从脂肪组织到肝脏的游离脂肪酸回流增加、肝细胞脂毒性、慢性坏死性炎症的刺激以及纤维化反应。随着技术的最新进展，先进的影像学技术为诊断提供了重要信息。目前在开发利用潜在的新型生物标志物对疾病进展至纤维化以及对治疗的反应进行无创监测方面有大量的研究工作，以便于诊断晚期肝硬化并尽量减少肝活检的需要。应将NAFLD的识别作为2型糖尿病患者常规评估的一部分，如同对微血管并发症和心血管疾病的评估一样，因为这对早期诊断和适当干预至关重要。饮食、运动训练和减肥具有显著的临床益处，必须被视为治疗NAFLD的一线方法。
Nonalcoholic fatty liver disease (NAFLD) is the most common, chronic liver disease worldwide. Within this spectrum, steatosis alone is apparently benign, while nonalcoholic steatohepatitis may progress to cirrhosis and hepatocellular carcinoma. NAFLD is strongly associated with obesity, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease. The pathogenesis of hepatic steatosis is not clearly known, but its main characteristics are considered insulin resistance, mitochondrial dysfunction, increased free fatty acids reflux from adipose tissue to the liver, hepatocyte lipotoxicity, stimulation of chronic necroinflammation, and fibrogenic response. With recent advances in technology, advanced imaging techniques provide important information for diagnosis. There is a significant research effort in developing noninvasive monitoring of disease progression to fibrosis and response to therapy with potential novel biomarkers, in order to facilitate diagnosis for the detection of advanced cirrhosis and to minimize the need of liver biopsy. The identification of NAFLD should be sought as part of the routine assessment of type 2 diabetics, as sought the microvascular complications and cardiovascular disease, because it is essential for the early diagnosis and proper intervention. Diet, exercise training, and weight loss provide significant clinical benefits and must be considered of first line for treating NAFLD.
登录
查看更多内容
影响因子：
9.8
作者：
Adams, Leon A.;Harmsen, Scott;St Sauver, Jennifer L.;Charatcharoenwitthaya, Phunchai;Enders, Felicity B.;Therneau, Terry;Angulo, Paul
通讯作者：
Angulo, Paul
影响因子：
29.4
作者：
Baumeister, Sebastian E.;Voelzke, Henry;Alte, Dietrich
通讯作者：
Alte, Dietrich
影响因子：
2.9
作者：
Gholam, PM;Kotler, DP;Flancbaum, LJ
通讯作者：
Flancbaum, LJ
影响因子：
4.2
作者：
Cusi, Kenneth
通讯作者：
Cusi, Kenneth
DOI：
10.5114/aoms.2011.25554
发表时间：
2011-10
期刊：
Archives of medical science : AMS
影响因子：
--
作者：
Athyros VG;Giouleme O;Ganotakis ES;Elisaf M;Tziomalos K;Vassiliadis T;Liberopoulos EN;Theocharidou E;Karagiannis A;Mikhailidis DP
通讯作者：
Mikhailidis DP